ArticleIranian journal of otorhinolaryngology2026
The Effects of Curcumin on Olfactory Dysfunction and Indoxyl Sulphate in Hemodialysis Patients.
Article in Iranian journal of otorhinolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Neurological abnormalities in uremic conditions are indicated by olfactory impairment in the population with long-term renal disease, which escalates in prevalence with the degree of severity of renal disease. Indoxyl Sulphate is a kind of toxic substance that exacerbates kidney damage. Since it scavenges ROS or reactive oxygen species, curcumin helps prevent disease development and promotes olfactory ensheathing cell growth and viability under normal and hypoxic settings. Materials and Methods: For 12 weeks, 48 patients with stage 5 chronic renal disease receiving regular haemodialysis were split into three groups: the control group, the 500 mg curcumin group, and the 1000 mg curcumin group. Plasma indoxyl Sulphate concentrations and subsequent olfactory function were assessed. The results were compared using bivariate and multivariate analysis. Results: The olfactory function delta (p=0.002) and discrimination of olfactory delta (p=0.001) of the 500 mg and 1000 mg curcumin groups differed significantly. The 500 mg curcumin group's IS levels (p=0.008) and the control group's (p=0.019) delta IS level (p=0.870) were significantly different from the 1000 mg curcumin olfactory group's olfactory identification (p=0.006) and delta identification (p=0.618). The olfactory thresholds of the three study groups did not differ significantly (p=0.636). Conclusion: Curcumin therapy alleviated olfactory impairment in individuals with chronic renal illness; no increase in indoxyl Sulphate levels was observed, suggesting that curcumin may stabilize the toxin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.